Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Loeb

Showing results (11-20 of 339) with videos related to

Pageof 34
Sort By:
American Family Physician|July 20, 2002
Community-acquired pneumoniaMark Loeb
ACP Journal Club|January 9, 2004
34% mortality rate from SARS in critically ill patients at 28 days in TorontoMark Loeb
BMJ Clinical Evidence|March 23, 2011
Community-acquired pneumoniaMark Loeb
Evidence-Based Medicine|June 10, 2010
The 23-valent polysaccharide vaccine prevents pneumococcal pneumonia and reduces associated mortality in nursing home residents in JapanMark Loeb
BMJ Clinical Evidence|May 19, 2009
Community-acquired pneumoniaMark Loeb
ACP Journal Club|January 9, 2004
37% mortality rate from SARS in critically ill patients at 28 days in SingaporeMark Loeb
Clinical Evidence|September 2, 2005
Community acquired pneumoniaMark Loeb
Annals of Internal Medicine|April 5, 2021
Joint testing of IgM and IgG has high value for ruling in SARS-CoV-2 infectionMark Loeb
BMJ Clinical Evidence|December 5, 2015
Community-acquired pneumonia: pneumococcal vaccineMark Loeb
Aging Clinical and Experimental Research|July 27, 2019
The burden of influenza in older adults: meeting the challengeJessica Bartoszko, Mark Loeb
Pageof 34

Showing results (11-20 of 339) with videos related to

Sort By:
Pageof 34
American Family Physician|July 20, 2002
Community-acquired pneumoniaMark Loeb
ACP Journal Club|January 9, 2004
34% mortality rate from SARS in critically ill patients at 28 days in TorontoMark Loeb
BMJ Clinical Evidence|March 23, 2011
Community-acquired pneumoniaMark Loeb
Evidence-Based Medicine|June 10, 2010
The 23-valent polysaccharide vaccine prevents pneumococcal pneumonia and reduces associated mortality in nursing home residents in JapanMark Loeb
BMJ Clinical Evidence|May 19, 2009
Community-acquired pneumoniaMark Loeb
ACP Journal Club|January 9, 2004
37% mortality rate from SARS in critically ill patients at 28 days in SingaporeMark Loeb
Clinical Evidence|September 2, 2005
Community acquired pneumoniaMark Loeb
Annals of Internal Medicine|April 5, 2021
Joint testing of IgM and IgG has high value for ruling in SARS-CoV-2 infectionMark Loeb
BMJ Clinical Evidence|December 5, 2015
Community-acquired pneumonia: pneumococcal vaccineMark Loeb
Aging Clinical and Experimental Research|July 27, 2019
The burden of influenza in older adults: meeting the challengeJessica Bartoszko, Mark Loeb
Pageof 34